Skip to main content
Retour
AZN logo

AstraZeneca PLC

Qualité des données : 100%
AZN
NYSE Healthcare Drug Manufacturers - General
184,07 €
▲ 0,47 € (0,26%)
Cap. Boursière : 142,68B
Fourchette du Jour
183,80 € 186,78 €
Fourchette 52 Semaines
122,48 € 212,71 €
Volume
2 009 369
Moyenne 50J / 200J
193,92 € / 169,71 €
Clôture Précédente
183,60 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (626 pairs)

Métrique Action Médiane du Secteur
P/E 13,9 0,4
P/B 2,9 2,9
ROE % 22,9 3,7
Net Margin % 17,5 3,8
Rev Growth 5Y % 11,9 10,0
D/E 0,6 0,2

Points Clés

Revenue grew 11,93% annually over 5 years — strong growth
Earnings grew 45,77% over the past year
ROE of 22,93% indicates high profitability
Net margin of 17,46% shows strong profitability
Generating 11,77B in free cash flow
P/E of 13,91 — trading at a low valuation

Croissance

Revenue Growth (5Y)
11,93%
Revenue (1Y)8,63%
Earnings (1Y)45,77%
FCF Growth (3Y)33,85%

Qualité

Return on Equity
22,93%
ROIC13,15%
Net Margin17,46%
Op. Margin23,40%

Sécurité

Debt / Equity
0,61
Current Ratio0,94
Interest Coverage8,11

Valorisation

P/E Ratio
13,91
P/B Ratio2,93
EV/EBITDA12,13
Dividend Yield0,04%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 8,63% Revenue Growth (3Y) 13,23%
Earnings Growth (1Y) 45,77% Earnings Growth (3Y) 31,23%
Revenue Growth (5Y) 11,93% Earnings Growth (5Y) 209,34%
Profitability
Revenue (TTM) 58,74B Net Income (TTM) 10,26B
ROE 22,93% ROA 8,99%
Gross Margin 81,90% Operating Margin 23,40%
Net Margin 17,46% Free Cash Flow (TTM) 11,77B
ROIC 13,15% FCF Growth (3Y) 33,85%
Safety
Debt / Equity 0,61 Current Ratio 0,94
Interest Coverage 8,11 Dividend Yield 0,04%
Valuation
P/E Ratio 13,91 P/B Ratio 2,93
P/S Ratio 2,43 PEG Ratio 0,07
EV/EBITDA 12,13 Dividend Yield 0,04%
Market Cap 142,68B Enterprise Value 166,67B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 58,74B 54,07B 45,81B 44,35B 37,42B
Net Income 10,26B 7,04B 5,96B 3,29B 112,00M
EPS (Diluted) 13,08 4,50 7,62 4,22 0,16
Gross Profit 48,11B 43,87B 37,54B 31,96B 24,98B
Operating Income 13,74B 10,00B 8,19B 3,76B 1,06B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 114,07B 104,04B 101,12B 96,48B 105,36B
Total Liabilities 65,36B 63,16B 61,95B 59,43B 66,08B
Shareholders' Equity 48,67B 40,79B 39,14B 37,04B 39,27B
Total Debt 29,70B 30,11B 28,62B 29,14B 30,69B
Cash & Equivalents 5,71B 5,49B 5,84B 6,17B 6,33B
Current Assets 28,72B 25,83B 25,05B 22,59B 26,24B
Current Liabilities 30,62B 27,87B 30,54B 26,29B 22,59B

Scores de Stratégies

This stock passed the criteria for 5 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#292 of 1024
55
Custom Capital Light Compounder
#136 of 213
35
Growth + Value Growth at a Reasonable Price (Peter Lynch)
#262 of 326
37
Custom Balanced Risk
#59 of 148
48
Custom Lower Risk
#70 of 136
45

Activité Récente

Entré Cash Flow Compounder
Mar 24, 2026
Entré Capital Light Compounder
Mar 24, 2026
Entré Growth at a Reasonable Price (Peter Lynch)
Mar 24, 2026
Entré Balanced Risk
Mar 24, 2026
Entré Lower Risk
Mar 24, 2026